

1 LAMP based assay can rectify the diagnosis of *Yersinia pseudotuberculosis*
2 infections otherwise missed by serology

3
4 Atsushi Kato¹, Ippei Miyata¹, Yuhei Tanaka¹, Tomohiro Oishi¹, Hideto
5 Teranishi¹, Hiroto Akaike¹, Naoki Ohno¹, Hiroshi Nakajima², Yutaka
6 Kouguchi³, Kazunobu Ouchi¹

7
8 ¹ Department of Pediatrics, Kawasaki Medical School

9 ² Bacteriology Section, Okayama Prefectural Institute for Environmental
10 Science and Public Health

11 ³ Department of Clinical Laboratory, Kawasaki Medical School Hospital

12
13 Address for correspondence: Ippei Miyata, MD, PhD.

14 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan

15 Facsimile: +81-86-464-1038, phone: +81-86-462-1111 (ext. 44132)

16 E-mail: miyata.KKCL@gmail.com.

17
18 Key words: *Yersinia pseudotuberculosis*, LAMP, bacterial culture, serological
19 testing

20
21 Subject: Clinical Microbiology

22
23 Word count: 2122 words

24
25 List of abbreviations: LAMP, loop-mediated isothermal amplification; Y.pstb,
26 *Yersinia pseudotuberculosis*; KD, Kawasaki disease; CT-SMAC, MacConkey
27 agar with sorbitol, cefixime, and tellurite; TCBS, thiosulfate citrate bile salts
28 sucrose; BTB, bromothymol blue lactose; SS, Salmonella-Shigella; IVIG,
29 intravenous immunoglobulin therapy.

30 **Abstract** (241 words)

31 **Background** Despite being a well-known but seldom encountered zoonotic
32 pathogen, diagnosis of *Yersinia pseudotuberculosis* is not necessarily easy.
33 Infected patients occasionally present with various symptoms resembling
34 Kawasaki disease; thus discriminating the two in the acute phase is
35 challenging. In addition to bacterial culture and serology, novel detection
36 methods based on loop-mediated isothermal amplification (LAMP) are
37 reported in the literature. However, the clinical utility of LAMP based
38 methods in comparison with the other methods is scarcely documented in the
39 literature.

40 **Aim** To clarify the clinical utility of LAMP based method in the diagnosis of
41 *Yersinia pseudotuberculosis* infection.

42 **Methodology** Inpatients admitted due to suspected *Yersinia*
43 *pseudotuberculosis* infection during April 2008 thru March 2015 were
44 enrolled. Results of LAMP based method as well as culture and serology
45 were collected and compared.

46 **Results/Key findings** Among 16 eligible cases, serology proved positive in 13
47 (81.3%) cases, LAMP in 8 (50%) cases, and bacterial culture in 4 (25%) cases.
48 No significant difference among the three methods could be proved
49 statistically. Though serology was the most sensitive method, it is known to
50 miss cases such as young patients, whereas LAMP could complement all 3
51 cases missed by serology. Furthermore, LAMP can return the test result
52 within a few hours from specimen receipt, whereas serology and bacterial
53 culture requires days to weeks of time.

54 **Conclusion** Although second to serology in sensitivity, the LAMP based
55 method proved its utility in making rapid diagnosis, and serving a
56 complementary role to serology.

57 **Introduction**

58 *Yersinia pseudotuberculosis* (Y.pstb) is a causative agent of acute enteritis
59 with various complications. Approximately 8% of Y.pstb cases are known to
60 present with manifestations resembling Kawasaki disease (KD) [1]. The
61 clinical symptoms that Y.pstb infection share with KD are: continuous fever,
62 conjunctivitis, strawberry tongue, cracked lips, cervical lymphadenopathy,
63 rashes. Therefore, early stage discrimination between Y.pstb infection and
64 KD is challenging. Indeed, no diagnostic method to distinguish between the
65 two at the early phase is established to date.

66 Despite being a well-known zoonotic pathogen, rapid identification of Y.pstb
67 is not easy. Isolation by culture requires several weeks. Furthermore, the
68 detection rate by direct stool culture is reported to be low (approximately one
69 third of confirmed cases), requiring cold enrichment to increase chance of
70 detection [2, 3]. Serologic tests are cumbersome, not widely available, and
71 also require several days. Furthermore, serologic tests are not standardized,
72 hindering comparison among studies.

73 Loop-mediated isothermal amplification (LAMP) is a nucleic acid
74 amplification method, which is widely used for detection of pathogenic
75 microorganisms, i.e. central nervous system infections, respiratory infections,
76 gastrointestinal tract infections including food poisoning [4-8]. A LAMP
77 assay to detect Y.pstb DNA with high sensitivity and specificity is also
78 reported [9].

79 Although some literature reporting the clinical utility of LAMP assay in
80 diagnosing Y.pstb infection can be found [10], no direct comparison of the
81 detection rates of Y.pstb among LAMP assay, serological testing, and culture
82 has been reported yet.

83 The objective of this study is to compare the detection rates of Y.pstb
84 infection among LAMP assay, serological testing, and culture test.

85

86 **Materials and Methods**

87 **Study population**

88 All patients suspected of Y.pstb infection, admitted to the Department of
89 Pediatrics, Kawasaki Medical School Hospital during April 2008 thru
90 March 2015 were enrolled. Patients presenting with both continuous fever
91 and gastrointestinal symptoms, accompanied by at least one of the
92 following five features — conjunctivitis, changes in the oral cavity and/or

lips, cervical lymphadenopathy, rash, changes in the extremities — were suspected of *Y.pstb* infection. Patients that underwent testing by all three testing methods described hereafter were considered eligible and included in the study. Written informed consent was obtained from the patients' guardian prior to specimen collection.

Specimen collection

Stool specimens were collected from enrolled patients on admission; each specimen was divided into two; one immediately subjected to bacterial culture, the other stored at -80°C until DNA extraction followed by LAMP assay was carried out.

Serum specimens were collected in the acute and convalescent stage and stored at -80°C until serological assay was carried out.

Diagnostic Methods

A case was diagnosed as *Y.pstb* infection when any of the following three methods proved positive: LAMP assay, serological testing, or culture.

LAMP assay

DNA was extracted from thawed frozen stool using QIAamp DNA Stool Mini kit (QIAGEN GmbH, Hilden Germany) according to the manufacturer supplied instructions; instead of weighing 180–220mg of stool, starting material was dispensed using the built-in spoon of 80.734 faeces container (Sarstedt K.K., Tokyo, Japan), a spoonful of which is approximately 200mg: In brief, a spoonful of stool per specimen was dispensed and subjected to DNA extraction using the kit, finally eluted with 200 μL of Buffer AE (10 mM Tris-HCl, 0.5 mM EDTA (pH 9.0)). Primer sequences, primer concentrations, and reaction conditions were adopted from the literature [9]. Oligonucleotide primers were ordered from Sigma-Aldrich Japan (Tokyo, Japan), used with Loopamp DNA Amplification Kit (Eiken Chemical Co., Ltd., Tokyo, Japan). In brief, 5 μL of the DNA eluate was subjected to a 25 μL LAMP reaction. The reaction was carried out at 63°C for 60 minutes on Loopamp Realtime Turbidimeter LA-500 (Eiken); positive reactions were automatically determined by the build-in feature of the turbidimeter.

129 **Stool culture**

130 Cold enrichment was carried out along with standard bacterial
131 isolation.

132 For standard bacterial isolation, the stool specimen was plated onto the
133 following five agar plates; MacConkey agar with sorbitol, cefixime, and
134 tellurite (CT-SMAC) (Kyokuto Pharmaceutical Industrial Co., Ltd.,
135 Tokyo, Japan), thiosulfate citrate bile salts sucrose (TCBS) agar (Nissui
136 Pharmaceutical Co., Ltd., Tokyo, Japan), Skirrow's Medium (Eiken),
137 bromothymol blue lactose (BTB) agar (Kyokuto), and
138 Salmonella-Shigella (SS) agar (Kyokuto).

139 For cold enrichment, 0.5mL of BHI bouillon (Nissui) was added to 9mL
140 of pre-cooled normal saline, into which an approximately 5mm sized
141 piece of stool was suspended. The suspension was incubated at 4°C for 3
142 weeks, during which 10µL of the suspension was inoculated onto BTB
143 agar and SS agar every 7 days.

144 Agar plates were incubated under the following conditions: CT-SMAC
145 and TCBS, 37°C for 2days; Skirrow's Medium, 42°C for 2days; BTB and
146 SS, 25°C for 5days.

147 Species identification of grown colonies was carried out using API 20E
148 identification kit (SYSMEX bioMérieux Co., Ltd., Tokyo, Japan).

149

150 **Serological testing**

151 Serological testing was carried out by direct agglutination. Patient
152 serum was diluted 1:10 by normal saline following heat inactivation at
153 56°C for 30 min, from which a 2-fold serial dilution series of 1:10 to 1:320
154 was prepared.

155 Whole bacterial cells were used as test antigens. Test antigen
156 suspensions were prepared from a panel of Y.pstb strains of the following
157 subserogroups, maintained and stocked at Okayama Prefectural
158 Institute for Environmental Science and Public Health; 1a, 1b, 2a, 2b, 3,
159 4a, 4b, 5a, 5b, and 6. Each strain was plated on BD BBL Trypticase soy
160 agar (Nippon Becton Dickinson Company, Ltd., Tokyo, Japan), incubated
161 2 days at 25°C, before working suspensions were prepared. The
162 two-night cultures were washed twice with normal saline, after which a
163 working suspension of each strain, adjusted to a turbidity of McFarland
164 standard No. 0.6, was prepared. 0.2mL of each suspension was mixed

165 with equal volumes of serial dilution series of patient serum, incubated
166 at 50°C overnight. The titer of a specimen was determined as the
167 maximum dilution in which agglutination was observed.

168 A case was determined serologically positive if the titer exceeded 1:160
169 in any serum specimen [11].

171 **Statistical analysis**

172 Statistical analyses were performed using R software (version 3.2.0; R
173 Core Team [<http://www.R-project.org/>]).

175 **Results**

176 During the study period, 32 patients were admitted for *Y.pstb* infection.
177 Among these patients, 16 underwent all three testing methods and were
178 considered eligible for direct comparison and enrolled in the study.
179 Characteristics of the 16 patients are summarized in Table 1; their median
180 age was 64 months (interquartile range, 26.75–106.25), 12 (75%) were male,
181 8 met the diagnostic criteria of KD among whom 6 received intravenous
182 immunoglobulin therapy (IVIG) whereas 2 were spared from IVIG due to
183 defervescence within 5 days, 13 had been administered antibiotics prior to
184 admission.

185 Results of LAMP assay, serological testing, and stool culture are also shown
186 in Table 1. Among the 16 cases, 8 (50%) by LAMP assay, 13 (81%) by
187 serological testing, and 4 (25%) by stool culture proved positive for *Y.pstb*. All
188 3 cases missed by serological testing were successfully detected by LAMP
189 assay. One out of the 3 cases proved positive by culture as well. LAMP assay
190 detected all 4 cases detected by fecal culture. All 4 culture positive cases
191 proved positive with the aid of cold enrichment; none proved positive for
192 *Y.pstb* by mere direct plating. LAMP demonstrated 100% sensitivity and 67%
193 specificity for culture positive cases, whereas serology 75% sensitivity and
194 17% specificity. (Table 2B, 2C)

195 The detection rates tended to be higher in the following order, serological
196 testing, LAMP assay, and stool culture. However, no significant difference
197 was noted between any pair among the three methods by Fisher's exact test
198 (serology vs. LAMP, $p=0.2$; LAMP vs. culture, $p=0.077$; serology vs. culture,
199 $p=1$). (Table 2A-C)

201 **Discussions**

202 LAMP assay could detect half of the cases in the early stage of *Y.pstb*
203 infection. Furthermore, LAMP assay bears the potency of returning results
204 extremely rapidly; typically within a few hours from specimen reception. The
205 detection rate of LAMP assay proved two times higher than stool culture,
206 whereas two times lower than serological testing, though no significant
207 differences between either LAMP assay and serological testing, or LAMP
208 assay and stool culture was found. No cases positive by stool culture was
209 missed by LAMP assay. In this study, LAMP proved 100% sensitivity and
210 67% specificity for culture positive cases, whereas serology 75% sensitivity
211 and 17% specificity; however, due to the small number of cases,
212 interpretation of these results deserve deliberation. Notable is the fact that
213 LAMP assay successfully detected all 3 cases that were missed by serological
214 analysis. Previous studies point out that serological testing can miss cases,
215 especially young cases [3, 12, 13]; one of the missed cases in our study is an
216 18-month old patient. LAMP assay might serve a complementary role to
217 serological testing in the diagnosis of such patients.

218 There were 8 cases of *Y.pstb* infection which were clinically diagnosed as
219 KD, among which 6 cases received IVIG therapy. Among the 8 cases, 4 cases
220 proved *Y.pstb* positive by LAMP assay. Early initiation of IVIG therapy,
221 typically within 5 days of onset, is recommended for KD in order to reduce
222 the risk of developing lifelong coronary sequelae — coronary artery
223 aneurysms. Contrariwise, *Y.pstb* infections are considered benign and
224 self-limiting, deserving no specific treatments including antibiotics, except
225 for severe cases [1, 14]. Although whether *Y.pstb* infection fulfilling the
226 diagnosis criteria of KD deserve IVIG therapy or not is yet to be determined
227 [1, 14, 15], rapid diagnosis by LAMP assay might provide a feasible method
228 for further investigation and/or treatment of such cases.

229 Furthermore, LAMP assay is advantageous to PCR based methods in the
230 following aspects. Its utility lies in the feasibility – isothermal amplification
231 that abolishes the use of thermal cyclers, and a far more efficient
232 amplification surpassing that of PCR, resulting in shortened amplification
233 time of typically 15-60 minutes, whereas typical real-time PCR requires
234 somewhat longer reaction time exceeding 1 hour and a costly real-time PCR
235 apparatus[4, 16-18]. The efficient amplification of LAMP also results in
236 precipitation of magnesium pyrophosphate, which can be observed as

237 turbidity in reaction tubes that can be discriminated by the naked eye [19];
238 in contrast, amplification of DNA by conventional PCR by gel electrophoresis
239 requires approximately another hour or more.

240 The authors are aware of the following limitations. First, no consensus
241 whether stool culture is a suitable surrogate marker for systemic *Y.pstb*
242 infection is established yet. The fact that serology was superior to stool
243 culture might serve as another proof for this limitation. A case report in the
244 literature [20] describing a case of *Y.pstb* infected patient from whom the
245 bacteria was detected only from biopsied lymph node is also suggestive.
246 Since *Y.pstb* grows slowly, it is likely to be obscured by outgrowth of other
247 flora in the stool specimen. The optimal phase for stool specimen collection
248 for successful culture of the bacteria is also not clear. Early administration of
249 antibiotics might have further reduced the chance of collecting suitable
250 specimen for successful culture testing. Although the detection rate of *Y.pstb*
251 by culture was in concordance with the past literature [3], this might have
252 been an underestimation, since most, if not all, subjects were administered
253 antibiotics prior to admission. Due to continuing fever and the difficulty of
254 establishing a definitive diagnosis at the early stage of the disease, patients
255 with *Y.pstb* infection are prescribed antibiotics more often than not.
256 Although direct plating could not prove *Y.pstb* in any cases, cold enrichment
257 proved effective in culturing *Y.pstb* in 4 cases, among which 3 cases had been
258 administered antibiotics prior to specimen collection. (Table 1)

259 Second, serological analyses were performed against 10 subserogroups
260 covering most of the cases in Japan. Since 21 subserogroups, 18 among
261 which with known pathogenicity against humans, are known to date [21], we
262 might have missed cases caused by the rare untested subserogroups.
263 Furthermore, the prevailing endemic subserogroups of the bacteria differ
264 geographically. Thus, comparison of our results with others would require
265 attention to the test antigens employed, and the region from which the study
266 population were recruited as well.

267 The authors are also aware of the lack of healthy controls; however due to
268 the following reasons, this is not a critical flaw in design. Healthy
269 individuals are reported to present with antibody titers less than 1:160 [22,
270 23], and the titers are also known to elevate spontaneously, diminishing
271 within 4 months [24]. Furthermore, only symptomatic subjects are known to
272 yield positive culture [25].

273 Currently, *Y.pstb* infected patients fulfilling the diagnosis criteria of KD are
274 recommended to undergo IVIG treatment. Further studies to investigate
275 whether such cases deserve IVIG administration are warranted. LAMP
276 assay in early stage diagnosis of *Y.pstb* infection might play an indispensable
277 role in these studies.

278 In conclusion, our results suggest that LAMP assay bears the potency of
279 rapid diagnosis in the early stage of *Y.pstb* infection, returning the assay
280 result to the clinical scene within a few hours from stool specimen receipt,
281 which neither serological testing nor bacterial culture can achieve. Its
282 clinical utility as a complementary measure to serological testing was also
283 suggested.

284

285 **Ethics**

286 This study was approved by the Institutional Review Board of Kawasaki
287 Medical School. (No. 1189)

288

289 **Funding information**

290 This study was supported by grant to AK from the Kawasaki Medical School.

291

292 **Acknowledgments**

293 The authors thank Ms. Nanae Ohzono, Ms. Keiko Fujioka, Ms. Mika
294 Hamaoka, Ms. Mizuho Yamagata, and Ms. Mika Suwa for technical
295 assistance.

296

297 **Conflicts of interest**

298 IM received manuscript fee from Eiken Chemical Co., Ltd. Other authors
299 have no conflicts of interest relevant to the content of this article.

300 **References**

- 301 1. **Zakhour R, Heresi GP, Murphy JR.** *Yersinia pseudotuberculosis*. In:
302 Kliegman RM, Stanton BF, St Geme JW, 3rd, Schor NF, Behrman RE
303 (editors). *Nelson Textbook of Pediatrics*, 20th ed. Philadelphia, PA:
304 Elsevier; 2015. p. 1408.
- 305 2. **Sato K, Ouchi K, Taki M.** *Yersinia pseudotuberculosis* infection in
306 children, resembling Izumi fever and Kawasaki syndrome. *Pediatric*
307 *infectious disease* 1983;2:123–126.
- 308 3. **Ouchi K, Sato K, Takahashi R, Taki M, Tateishi K.** [Significance of
309 ruling out *Yersinia pseudotuberculosis* infection from Kawasaki
310 Disease]. *J Jpn Pediatr Soc* 1985;89:449–454. [In Japanese]
- 311 4. **Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K et al.**
312 Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res*
313 2000;28:E63.
- 314 5. **Kimura H, Ihira M, Enomoto Y, Kawada J, Ito Y et al.** Rapid detection
315 of herpes simplex virus DNA in cerebrospinal fluid: comparison
316 between loop-mediated isothermal amplification and real-time PCR.
317 *Med Microbiol Immunol* 2005;194:181–185.
- 318 6. **Hong TC, Mai QL, Cuong DV, Parida M, Minekawa H et al.**
319 Development and Evaluation of a Novel Loop-Mediated Isothermal
320 Amplification Method for Rapid Detection of Severe Acute Respiratory
321 Syndrome Coronavirus. *J Clin Microbiol* 2004;42:1956–1961.
- 322 7. **Song T, Toma C, Nakasone N, Iwanaga M.** Sensitive and rapid
323 detection of *Shigella* and enteroinvasive *Escherichia coli* by a
324 loop-mediated isothermal amplification method. *FEMS Microbiol Lett*
325 2005;243:259–263.
- 326 8. **Yamazaki W, Taguchi M, Kawai T, Kawatsu K, Sakata J et al.**
327 Comparison of loop-mediated isothermal amplification assay and
328 conventional culture methods for detection of *Campylobacter jejuni*
329 and *Campylobacter coli* in naturally contaminated chicken meat
330 samples. *Appl Environ Microbiol* 2009;75:1597–1603.
- 331 9. **Horisaka T, Fujita K, Iwata T, Nakadai A, Okatani AT et al.** Sensitive
332 and specific detection of *Yersinia pseudotuberculosis* by loop-mediated
333 isothermal amplification. *J Clin Microbiol* 2004;42:5349–5352.
- 334 10. **Sakai N, Ohtsuka Y, Oka M, Ichimaru T, Tashiro K et al.** A case of
335 *Yersinia pseudotuberculosis* infection with renal failure: the LAMP

- 336 method was helpful to make the diagnosis. *Japanese journal of*
337 *pediatric nephrology* 2010;23:102–106.
- 338 11. **Tsubokura M.** Yersinioses Other than Plague. In: Balows A, Hausler
339 WJJ, Ohashi M, Turano A (editors). *Laboratory Diagnosis of Infectious*
340 *Diseases: Principles and Practice*. New York, NY: Springer-Verlag;
341 1988. pp. 540–549.
- 342 12. **Marks MI, Pai CH, Lafleur L, Lackman L, Hammerberg O.** *Yersinia*
343 *enterocolitica* gastroenteritis: a prospective study of clinical,
344 bacteriologic, and epidemiologic features. *J Pediatr* 1980;96:26–31.
- 345 13. **Sato K, Ouchi K, Komazawa M.** Ampicillin vs. placebo for *Yersinia*
346 *pseudotuberculosis* infection in children. *Pediatr Infect Dis J*
347 1988;7:686–689.
- 348 14. **Gould LH.** Yersiniosis. In: Centers for Disease Control and Prevention,
349 editor. CDC Health Information for International Travel 2016. New
350 York: Oxford University Press; 2015. pp. 362–363.
- 351 15. **Horinouchi T, Nozu K, Hamahira K, Inaguma Y, Abe J et al.** *Yersinia*
352 *pseudotuberculosis* infection in Kawasaki disease and its clinical
353 characteristics. *BMC Pediatr* 2015;15:177.
- 354 16. **Njiru ZK.** Loop-mediated isothermal amplification technology:
355 towards point of care diagnostics. *PLoS Negl Trop Dis* 2012;6:e1572.
- 356 17. **Mori Y, Kanda H, Notomi T.** Loop-mediated isothermal amplification
357 (LAMP): recent progress in research and development. *J Infect*
358 *Chemother* 2013;19:404–411
- 359 18. **Li Y, Fan P, Zhou S, Zhang L.** Loop-mediated isothermal amplification
360 (LAMP): A novel rapid detection platform for pathogens. *Microb*
361 *Pathog* 2017;107:54–61.
- 362 19. **Mori Y, Nagamine K, Tomita N, Notomi T.** Detection of Loop-Mediated
363 Isothermal Amplification Reaction by Turbidity Derived from
364 Magnesium Pyrophosphate Formation. *Biochem Biophys Res*
365 *Commun* 2001;289:150–154.
- 366 20. **Fukushima H, Sato T, Nagasako R, Takeda I.** Acute mesenteric
367 lymphadenitis due to *Yersinia pseudotuberculosis* lacking a virulence
368 plasmid. *J Clin Microbiol* 1991;29:1271–1275.
- 369 21. **Fukushima H.** [Epidemiology of Pathogenic *Yersinia* and Their
370 Detection Method]. *Japanese Journal of Food Microbiology*
371 2011;28:104–113. [In Japanese]

- 372 22. **Leino R, Kalliomäki JL.** Yersiniosis as an internal disease. *Ann Intern*
373 *Med* 1974;81:458-461.
- 374 23. **Paff JR, Triplett DA, Saari TN.** Clinical and laboratory aspects of
375 *Yersinia pseudotuberculosis* infections, with a report of two cases. *Am*
376 *J Clin Pathol* 1976;66:101–110.
- 377 24. **Mair, NS.** Yersiniosis (Infections due to *Yersinia pseudotuberculosis*
378 and *Yersinia enterocolitica*). In: Hubbert WT, McCulloch WF,
379 Schnurrenberger PR (editors). *Diseases transmitted from animals to*
380 *man*, 6th ed. Springfield, IL: Charles C Thomas. Publisher; 1975.
381 pp.174–185.
- 382 25. **Maruyama T.** Yersiniosis as zoonoses. *J. Jpn. Vet. Med. Assoc*
383 1982;35:2–8. [In Japanese]

384
385

Table 1. Profiles and assay results of all eligible cases.

Case No.	Age (mo)	Gender	LAMP	Serology	Culture*	Prior Antibiotics	KD
1	27	M	+	+	+	+	+
2	15	M	+	+	+	+	+
3	107	F	+	+	+	+	
4	44	M	+	+	-	+	
5	23	M	+	+	-	+	
6	18	M	+	-	+	-	+
7	76	F	+	-	-	+	+
8	106	M	+	-	-	+	+†
9	26	F	-	+	-	+	+
10	34	M	-	+	-	+	+
11	120	M	-	+	-	+	+†
12	96	F	-	+	-	-	
13	52	M	-	+	-	+	
14	147	M	-	+	-	+	
15	94	M	-	+	-	n/d	
16	116	M	-	+	-	+	

386
387
388
389
390
391
392

* All culture positive specimens proved positive with the aid of cold enrichment.

† Spared from intravenous immunoglobulin therapy due to defervescence within 5 days of fever onset.

LAMP, loop-mediated isothermal amplification; KD, Kawasaki disease; n/d, no data

393 Table 2. Comparison among the 3 methods.

394 A)

		LAMP	
		+	-
Serology	+	5	8
	-	3	0

p=0.2
95%CI 0–2.21

395

396

397 B)

		LAMP	
		+	-
Culture	+	4	0
	-	4	8

p=0.077
95%CI 0.81–∞

398

399

400 C)

		Serology	
		+	-
Culture	+	3	1
	-	10	2

p=1
95%CI 0.02–47.07

401

402

403

404

+, positive; –, negative